Company Profile
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Latest News
Goldman Sachs leads oil and gas M&A advisory by value in H1 2026
Philippines' Marcos says 'perhaps time to revisit nuclear energy'
Camden National Bank Earnings: What To Look For From CAC
Black Book Expands Vendor-Agnostic Healthcare Supply Chain Technology Benchmark to 36 Categories for AHRMM26
Target Hospitality Announces New $660 Million Credit Facility, Significantly Expanding Liquidity and Lowering Cost of Capital to Support Strategic Growth
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.csl.com |
| Audit Risk | 7 |
| Board Risk | 4 |
| Overall Risk | 5 |
| Market Cap | 55.74B |
| Trailing P/E | 13.15 |
| Forward P/E | 12.77 |
| Dividend Rate | 4.26 |
| Dividend Yield | 3.66% |
| Trailing Annual Div. Rate | 2.92 |
| Trailing Annual Div. Yield | 2.56% |
| Trailing EPS | 8.85 |
| Forward EPS | 9.11 |
| Book Value | 55.45 |
| Price-to-Book | 2.1 |
| Enterprise-to-Revenue | 4.34 |
| Enterprise-to-EBITDA | 13.82 |
| Ex-Dividend Date | 03/10/2026 |
| Earnings Date | |
| Earnings Call Date |